ARA lncRNA, is upregulated in liver and breast tumor tissues

Raeisi, Farzaneh; Abolfathi, Mahdieh; Ahmadi-Naji, Raheleh; Iranparast, Sara; Noshadi, Esmat; Akbari, Arvand; Mahmoudi, Esmaeil; Khaledi, Mansoor; Arshi, Asghar

doi:10.1007/s11033-018-4447-6

Cited by 5 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To perform all statistical tests, REST 2009 and Graph Pad Prism statistical software, version 7.00 (Graph Pad, San Diego, CA, USA) were utilized. A P-value of <0.05 was considered statistically signi cant for all tests [19,20].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Potential of HOTAIR, MALAT1, and UCA1 lncRNAs As a Biomarker to Achieve More Accurate Prognostic Predictions for Liver Cancer

Mahmoudi

Ebrahimi

Chermahini

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is a major worldwide health concern and is the third leading cause of cancer death. Recent studies have focused on the association between long non-coding RNAs (lncRNAs) and cancer, lncRNAs showed to have an important role in the prognosis, diagnostic, and investigation of liver cancer. Therefore, this study focuses on the expression profiles of HOTAIR, MALAT1, and UCA1 lncRNAs considering the clinicopathological characteristics of patients with liver tumors. Methods and Results: The expression profiles of HOTAIR, MALAT1, and UCA1 lncRNAs were evaluated using qRT-PCR in the paired liver tumor and the adjacent non-tumor samples. After RNA extraction from tissue samples, cDNA synthesis and the RT-qPCR method were performed. Livak method (2-ΔΔCt) was used for calculating the expression level of lncRNAs. Principal-component analyses followed by receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic potential of the selected lncRNAs. Our results showed that HOTAIR, MALAT1, and UCA1 were overexpressed significantly in patients with liver cancer compared to the healthy groups (P < 0.001). Moreover, the expression of HOTAIR was enhanced significantly compared to the expression of MALAT1 and UCA1 in patients with liver cancer (P < 0.001). This study showed that there were no significant associations between lncRNAs expression and the clinical characteristics (P > 0.05). Significantly elevated circulating lncRNAs were found to be liver cancer-specific and showed differentiation of liver cancer samples from the controls. Kaplan-Meier analysis revealed no significant correlations between the lncRNAs expression and overall survival. Conclusion: Based on our findings, the studied lncRNAs were not correlated with clinicopathological characteristics of the liver cancer patients although the overexpression of these lncRNAs might provide novel molecular biomarkers in HCC cases.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The relative lncRNA concentration was calculated using the mean value in each triple (ΔCt=Ct mean lncRNA-Ct mean GAPDH). To calculate expression fold changes, 2 −ΔΔCt methods were used [19,20].…”

Section: Quantitative Real-time Pcrmentioning

confidence: 99%

Clinical Potential of HOTAIR, MALAT1, and UCA1 lncRNAs As a Biomarker to Achieve More Accurate Prognostic Predictions for Liver Cancer

Mahmoudi

Ebrahimi

Chermahini

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…LncRNAs are also involved in the development, proliferation, differentiation and apoptosis of cancer cells 98 - 100 . Multiple studies have shown that lncRNAs play an important role in the regulation of progression and metastasis in many types of cancer, such as hepatocellular carcinoma 101 , colorectal cancer 102 - 104 and breast cancer 105 , 106 .…”

Section: Detection Methods For Ctnasmentioning

confidence: 99%

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids

Wei

Xing

et al. 2020

J. Cancer

View full text Add to dashboard Cite

The diagnosis, treatment and prognosis of sarcoma are mainly dependent on tissue biopsy, which is limited in its ability to provide a panoramic view into the dynamics of tumor progression. In addition, effective biomarkers to monitor the progression and therapeutic response of sarcoma are lacking. Liquid biopsy, a recent technological breakthrough, has gained great attention in the last few decades. Nucleic acids (such as DNA, mRNAs, microRNAs, and long non-coding RNAs) that are released from tumors circulate in the blood of cancer patients and can be evaluated through liquid biopsy. Circulating tumor nucleic acids reflect the intertumoral and intratumoral heterogeneity, and thus liquid biopsy provides a noninvasive strategy to examine these molecules compared with traditional tissue biopsy. Over the past decade, a great deal of information on the potential utilization of circulating tumor nucleic acids in sarcoma screening, prognosis and therapy efficacy monitoring has emerged. Several specific gene mutations in sarcoma can be detected in peripheral blood samples from patients and can be found in circulating tumor DNA to monitor sarcoma. In addition, circulating tumor non-coding RNA may also be a promising biomarker in sarcoma. In this review, we discuss the clinical application of circulating tumor nucleic acids as blood-borne biomarkers in sarcoma.

show abstract

“…Long noncoding RNAs (lncRNAs) are non-protein-coding RNA molecules with a length of >200 nucleotides ( Ghafouri-Fard and Taheri, 2020 ). They are involved in the growth, proliferation, metastasis and drug resistance of cancers and other related processes and are abnormally expressed in various cancers, such as gastric, lung, breast, liver, and endometrial cancers ( Chen et al, 2016 ; Kim et al, 2018 ; Raeisi et al, 2019 ). LSD1 can bind to lncRNAs to exert oncogenic effects.…”

Section: Primary Targets or Signalling Pathways Mediated By Lsd1mentioning

confidence: 99%

Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A

Yang

Zang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Epigenetics has emerged as a prime focus area in the field of cancer research. Lysine-specific demethylase 1A (LSD1), the first discovered histone demethylase, is mainly responsible for catalysing demethylation of histone 3 lysine 4 (H3K4) and H3K9 to activate or inhibit gene transcription. LSD1 is abnormally expressed in various cancers and participates in cancer proliferation, apoptosis, metastasis, invasion, drug resistance and other processes by interacting with regulatory factors. Therefore, it may serve as a potential therapeutic target for cancer. This review summarises the major oncogenic mechanisms mediated by LSD1 and provides a reference for developing novel and efficient anticancer strategies targeting LSD1.

show abstract

ARA lncRNA, is upregulated in liver and breast tumor tissues

Cited by 5 publications

References 23 publications

Clinical Potential of HOTAIR, MALAT1, and UCA1 lncRNAs As a Biomarker to Achieve More Accurate Prognostic Predictions for Liver Cancer

Clinical Potential of HOTAIR, MALAT1, and UCA1 lncRNAs As a Biomarker to Achieve More Accurate Prognostic Predictions for Liver Cancer

The new horizon of liquid biopsy in sarcoma: the potential utility of circulating tumor nucleic acids

Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A

Contact Info

Product

Resources

About